Navigation Links
Lung Cancer Alliance-Massachusetts Issues Inaugural State-Specific Report Card on Lung Cancer
Date:11/28/2007

Massachusetts Receives Failing Grades on Key Benchmarks

WASHINGTON, Nov. 28 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance-Massachusetts (LCA-MA) issued its first-ever state-specific Report Card on Lung Cancer. The Report Card gauges the progress being made against this lethal disease by the state of Massachusetts. LCA-MA is a chapter of Lung Cancer Alliance (LCA).

Lung cancer is the number one cause of cancer deaths nationally, as well as among Massachusetts men and women, resulting in 30 percent of all cancer deaths in the state. This year alone lung cancer will take the lives of 3,630 Massachusetts citizens --- more than breast, prostate, and colon cancers -- combined.

"For the first time, we have benchmarks in place that will measure the progress of the Massachusetts public health establishment in reducing lung cancer's high mortality rates," said Diane Legg, Co-Chair of LCA-MA. "LCA-MA will ensure that lung cancer receives research funding commensurate to its public health impact in our state."

Said Laurie Fenton Ambrose, President and CEO of LCA, "This is an historic step forward for the Massachusetts lung cancer community and could not have happened without the dedication and determination of these remarkable advocates to reduce lung cancer mortality in Massachusetts."

The LCA-MA Report Card on Lung Cancer highlights six categories and annually evaluates and then grades the progress being made to eradicate this disease. This Report is a tool to educate the public as well as state leaders to the needs of the lung cancer community in Massachusetts.

The LCA-MA Report Card on Lung Cancer grades the following six categories:

-- Number of Deaths - GRADE: F Lung cancer is the number one cause of cancer death among Massachusetts men and women.

-- Five-Year Survival Rate - GRADE: F For nearly 40 years, there has been virtually no improvement in lung cancer's 15 percent five year sur
'/>"/>

SOURCE Lung Cancer Alliance
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...eille Guiliano’s bestseller ‘French Women Don’t Ge...nment figures, 5.9 million of France's 63.4 millio.... The figures have got the French government scra...e ways to come back to the former image of the sve...
...amin supplements and low fat dairy products in Bri...inding which was published// in The Journal of the...finding consumption of vitamin pills for a prolong...ality rate by 5% and low fat dairy may hamper the ...
...tain’s pay deals given by pay review bodies of the... millions of public sector workers across the coun...specially negative, in the medical sector. Healt... announced that GPs or family doctors will get a z...
Busting the Exam Blues
Other Medicine News:Health News:UK’s Health Services Totterin 2Health News:Busting the Exam Blues 2Health News:Busting the Exam Blues 3Health News:Busting the Exam Blues 4
(Date:5/20/2008)...ted in second half of 2008 --,-- Presentation at t...ce on, May 21st canceled; webcast of corporate up...lder Meeting on May 22nd at 9:30 a.m. PT --, SAN ...ciences, Inc.,(Nasdaq: RDEA ) today announced tha...-activated ERK kinase (MEK) inhibitor, RDEA119, de...
(Date:5/20/2008)...ire-FirstCall/ -- Telik, Inc.,(Nasdaq: TELK ), to...A(R),studies -- one with TELINTRA tablets in myelo...INTRA tablets in cancer patients at risk for,chemo...ly reported, Telik completed a successful 65 patie...RA in MDS, and a dose-escalating,Phase 1 study of ...
(Date:5/20/2008)...ented at Digestive Disease Week (DDW), SAN DIEGO,...ata,presented at Digestive Disease Week reaffirm t...imzia(R) (certolizumab pegol) at stable doses in,t...isease. Data also showed,continued remission among...te remained stable in many of the patients who wer...
(Date:5/20/2008)... bronchodilation and symptom control ..., May 20 /- A newly published study p...nic Obstructive Pulmonary Disease,(COPD), includin...rkedly,improved bronchodilation and symptom contro...moterol fumarate inhalation solution,(Perforomist(...
Breaking Medicine Technology:Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 2Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 3Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 4Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies 2Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies 3Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 2Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 3Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 5Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 6Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 7Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 8Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7MedQuist Reports First Quarter 2008 Results 5321 1MedQuist Reports First Quarter 2008 Results 5321 2MedQuist Reports First Quarter 2008 Results 5321 3MedQuist Reports First Quarter 2008 Results 5321 4MedQuist Reports First Quarter 2008 Results 5321 5MedQuist Reports First Quarter 2008 Results 5321 6MedQuist Reports First Quarter 2008 Results 5321 7MedQuist Reports First Quarter 2008 Results 5321 8MedQuist Reports First Quarter 2008 Results 5321 9Medical Research Should Include More Women Participants and Examine the Role of Gender in Disease Incidence and Treatment 19077 1Medical Research Should Include More Women Participants and Examine the Role of Gender in Disease Incidence and Treatment 19077 2Medical Research Should Include More Women Participants and Examine the Role of Gender in Disease Incidence and Treatment 19077 3Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference 5318 1Problem Gambling Common Among Young Adults 19073 1Problem Gambling Common Among Young Adults 19073 2
...Newswire-FirstCall/ --,Allos Therapeutics, Inc. to...Communities, with a favorable opinion of the Commi... Medicines Agency (EMEA),has granted orphan drug ...(pralatrexate) for the treatment of patients with,...he U.S. Food and,Drug Administration (FDA) awarded...
...hortly, CARMIEL, Israel, April 18, 2007 /PRNewswir...day announced that it has received,written notice ...n,(FDA) that it may initiate a Phase III clinical ...didate, prGCD, a proprietary plant,cell expressed ...,for the treatment of Gaucher Disease, a lysosoma...
Other Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 2Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 3
...r System combines precision with ease of operation...ns. The pneumatic motor powered system developed f...rocedures includes a drill, sagittal saw (extended...th available), reciprocating saw (extended length ...
Elmed Retract - Robot an single arm instrument, with extra long (10") horizontal extension for improved cephalad and anterior retraction. Retract - Robot (Retractor system) was designed to assist sur
Fortitude as a unique complement to the spinal concepts family of products.
As a unique complement to the spinal concepts family of products.
Medicine Products: